한글목차

8개 주요 국가의 크론병(CD) 치료제 시장 전체 매출은 2022년 약 95억 달러를 기록했습니다. 이 시장은 예측 기간이 끝나는 2032년까지 4.7%의 연평균 성장률(CAGR)로 95억 달러에서 150억 달러로 확대될 것으로 예상됩니다. 시장 성장의 원동력은 15개의 파이프라인, 제네릭 및 바이오시밀러 치료제의 승인 및 출시입니다.

이 보고서는 주요 8개국의 크론병 시장을 조사하여 질병 개요와 역학, 현재 치료법, 미충족 수요와 기회, 연구개발 동향, 지역별 전망 등을 정리했습니다.

목차

제1장 크론병 : 주요 요약

제2장 서론

제3장 질병 개요

• 병인학과 병태생리학
  • 병인
  • 병태생리학
  • CD 분류

제4장 역학

• 질병 배경
• 위험인자와 병존질환
• 세계적 및 역사적 동향
• 주요 8개국 시장 예측 조사 방법
• 크론병 역학 예측(2022-2032년)
• 논의

제5장 질병 관리

• 진단과 치료 개요
• 질병 관리에 관한 KOL의 인사이트

제6장 현재의 치료 선택사항

• 개요

제7장 미충족 수요와 기회 평가

• 개요
• 약효, 임상 반응 및 지속적 관해 개선
• 치료에 대한 반응성과 예후를 예측하기 위한 바이오마커
• 항문 주위 누공의 의학적 관리 개선
• 가장 효과적인 치료법을 결정하기 위한 임상 데이터

제8장 연구개발 전략

• 개요
• 임상시험 설계

제9장 파이프라인 평가

• 개요
• 임상 개발중인 유망한 약제

제10장 파이프라인 평가 분석

• 개요
• 경쟁력 평가

제11장 현재 및 향후 진출 기업

• 개요
• 거래 성립 동향

제12장 시장 전망

• 세계 시장
• 미국
• EU 5개국
• 일본
• 캐나다

제13장 부록

영문목차

Abstract

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for Crohn's Disease market through 2032.

GlobalData estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15.0 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.

Major drivers of CD market growth over the forecast period are the -

• The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
• Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
• Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Major barriers that will restrict the growth of the CD market during the forecast period are the -

• Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
• The emergence of several biosimilar and generic drugs entering the US market
• Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events

Key Highlights

• GlobalData estimates that sales of drugs in the CD market was approximately $9.5 billion in 2022 in the 8MM. The global CD market is expected to grow to $15.0 billion in 2032, at a Compound Annual Growth Rate (CAGR) of 4.7%.

Major drivers of CD market growth over the forecast period are the -

• The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
• The launch of the MK-7240 companion diagnostic test
• Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Scope

• Overview of CD including epidemiology, disease etiology and management.
• Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
• Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global CD therapeutics market from 2022-2032.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Crohn's Disease: Executive Summary

• 1.1 Steady growth is expected for the CD market from 2022-32
• 1.2 Novel MOAs will provide market shifts throughout the forecast period
• 1.3 Lack of tools to properly treat patients with CD is a clear unmet need within the market
• 1.4 Pipeline Drugs
• 1.5 What Do Physicians Think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 CD Classification

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 8MM forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
• 4.5 Epidemiological forecast for Crohn's disease (2022-32)
  • 4.5.1 Diagnosed incident cases of CD
  • 4.5.2 Age-specific diagnosed incident cases of CD
  • 4.5.3 Sex-specific diagnosed incident cases of CD
  • 4.5.4 Diagnosed prevalent cases of CD
  • 4.5.5 Age-specific diagnosed prevalent cases of CD
  • 4.5.6 Sex-specific diagnosed prevalent cases of CD
  • 4.5.7 Diagnosed prevalent cases of CD by severity
  • 4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
  • 4.5.9 Diagnosed prevalent cases of CD in remission by severity
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
• 7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
• 7.4 Improved Medical Management of Perianal Fistulas
• 7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Novel MOAs
  • 8.1.2 Biomarkers
• 8.2 Clinical Trials Design
  • 8.2.1 Patient inclusion criteria
  • 8.2.2 Endpoints

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive Assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-Making Trends

12 Market Outlook

• 12.1 Global Markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key Events
  • 12.4.3 Drivers and barriers
• 12.5 Canada
  • 12.5.1 Forecast
  • 12.5.2 Key events
  • 12.5.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting Methodology
• 13.4 Primary Research - KOLs Interviewed for This Report
  • 13.4.1 KOLs
• 13.5 Primary Research - Prescriber Survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Managing Analyst
  • 13.6.3 Epidemiologist
  • 13.6.4 Reviewers
  • 13.6.5 Global Director of Therapy Analysis and Epidemiology